Autres langues SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
40,22 ^USD	+1,28 %		-2,99 %	+10,19 %

05/06	Un initié de Springworks Therapeutics a vendu des actions pour une valeur de 801 372 $, selon un récent dépôt auprès de la SEC	MT
05/06	Un initié de Springworks Therapeutics a vendu des actions pour une valeur de 1 955 113 $, selon un récent dépôt auprès de la SEC	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SpringWorks Therapeutics : Termination of Material Agreement Form 8 K	22:20
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing	05/06
Springworks Therapeutics Insider Sold Shares Worth $1,955,113, According to a Recent SEC Filing	05/06
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05/06
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05
SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting	23/05
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference	08/05
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss	02/05
SpringWorks Therapeutics: Q1 Earnings Snapshot	02/05
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M	02/05
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	02/05
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	18/04
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04/03
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Autres langues

Filtres